美股异动丨诺和诺德盘前续涨4.4%，Wegovy口服片剂正式在美国上市

Core Viewpoint - Novo Nordisk (NVO.US) has launched the world's first oral GLP-1 medication for adult weight loss in the U.S., which is expected to enhance its market position and revenue potential [1] Group 1: Product Launch - The oral medication, Wegovy, is available in a starting dose of 1.5 mg [1] - Wegovy is now stocked in over 70,000 pharmacies across the U.S., including CVS and Costco [1] - Patients can purchase the starting dose at a price of $149 per month [1] Group 2: Market Impact - Following the announcement, Novo Nordisk's stock price increased by 4.4%, reaching $57.54 [1]